The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Open accessPublished version of a preprint
Abstract
The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)–based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Two doses of BNT162b2 elicited substantially reduced neutralizing activity against SARS-CoV-2 Omicron, while a third dose boosted Omicron-neutralizing titers to levels comparable to Wuhan-neutralizing titers after two doses in the pseudovirus assay. The data suggest that three BNT162b2 doses may protect against Omicron-mediated COVID-19.
Key findings
- After two BNT162b2 doses, Omicron pseudovirus-neutralizing GMTs were 7 versus 160 for Wuhan, a 22.8-fold reduction; 20 of 32 sera had no detectable Omicron neutralization. Beta and Delta GMTs were 24 and 73, corresponding to 6.7- and 2.2-fold reductions versus Wuhan.
- One month after a third dose, Omicron pseudovirus-neutralizing GMTs rose to 164, a 23.4-fold increase over post-dose-two levels and similar to Wuhan GMTs after two doses (160); 29 of 30 sera neutralized Omicron. Beta, Delta, and Wuhan GMTs after dose three were 279, 413, and 368.
- In live SARS-CoV-2 assays, two doses gave Omicron GMTs of 6 versus 368 for Wuhan, a 61.3-fold reduction, with 17 of 25 sera showing no detectable Omicron neutralization. After a third dose, Omicron GMTs increased 17.6-fold to 106 and remained 3.4-fold lower than Wuhan GMTs after two doses; 27 of 28 sera neutralized live Omicron.
- Among 244 HLA class I–restricted Wuhan S epitopes from IEDB, 85.3% (208) were unaffected at the amino acid sequence level in Omicron.
Methods
- Pseudovirus-neutralization tests used VSV-SARS-CoV-2-S pseudoviruses bearing Wuhan, Omicron, Beta, or Delta S proteins with sera from 32 BNT162-01 participants 21 days after dose two and 30 BNT162-14/BNT162-17 participants 1 month after dose three; 11 participants were analyzed longitudinally.
- Live SARS-CoV-2 neutralization tests used Wuhan and Omicron virus with sera from 32 and 25 participants after dose two, respectively, and 7 and 28 participants after dose three, respectively. Specimens were tested in duplicate and geometric mean 50% neutralizing titers were calculated.
- T cell analysis assessed 244 HLA class I–restricted S epitopes reported in IEDB for conservation in Omicron.
Limitations
- The paper states that serum panels came from different clinical trials with limited sample size, and the interval between second and third doses was not consistent across participants.
- The paper states that future analyses are needed to evaluate antibody persistence, and notes that a longer interval (>42 days) between first and second doses may improve immunogenicity but was not evaluated here.
- Evident from the text: the study reports neutralization titers, not clinical efficacy; live Omicron testing used smaller subsets than pseudovirus testing; and durability beyond 1 month after the third dose was not assessed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Own result · 13 Not checked yet · 8 Own interpretation · 3 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and were reduced 3.4-fold compared with those against the Wuhan reference at 21 days after two doses of BNT162b2 (GMT of 106 versus 368).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 28- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Sera from different clinical trials are comparable for neutralizing antibody analysis.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Twenty-nine of 30 serum specimens were capable of neutralizing the Omicron pseudovirus (table S3).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plainn = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After two doses of BNT162b2, geometric mean neutralization titers (GMTs) against Omicron pseudovirus were reduced 22.8-fold compared with those for the Wuhan reference pseudovirus (Fig. 1; GMT of 7 versus 160).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 32- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One month after the third BNT162b2 dose, neutralizing GMTs against the Omicron variant pseudovirus increased 23.4-fold relative to their levels 21 days after the second dose (GMT of 164 versus 7)”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Twenty of 32 immune serum specimens displayed no detectable neutralizing activity against Omicron (table S2).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plainn = 32- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neutralizing GMTs against live SARS-CoV-2 Omicron were reduced 61.3-fold relative to those against the Wuhan reference strain (Fig. 2; GMT of 6 versus 368) at 21 days after two doses of BNT162b2.”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Twenty-one days after dose two, sera exhibited a 21.4-fold reduction in GMT against the Omicron variant compared with the Wuhan reference pseudovirus (fig. S1; GMT of 7 versus 150).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One month after the third BNT162b2 dose, neutralizing GMTs against Omicron were increased 17.6-fold compared with neutralizing GMTs at 21 days after the second dose (GMT of 106 versus 6)”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 28- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seventeen of 25 serum specimens displayed no detectable neutralizing activity against Omicron (table S4).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plainn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and were comparable to neutralizing GMTs against the reference Wuhan pseudovirus at 21 days after two doses of BNT162b2 (GMT of 164 versus 160).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plainn = 30- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Sera from different clinical trials are comparable for neutralizing antibody analysis.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 7
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By contrast, the majority of sera neutralized Beta and Delta pseudoviruses with GMTs of 24 and 73, respectively. This corresponds to 6.7- and 2.2-fold reductions in neutralization activity compared with the Wuhan pseudovirus”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 32- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the third dose of BNT162b2 resulted in a significant increase in neutralizing titers against the Wuhan pseudovirus (GMT of 320) and a 25.8-fold increase in neutralizing titers against Omicron 1 month after dose three compared with 21 days after dose two (GMT of 181 versus 7).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirectn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Before receiving the third dose of BNT162b2 (at a median 256 days after dose two), neutralizing titers against the Wuhan pseudovirus were considerably reduced (GMT of 13), whereas the Omicron-specific titers were below the limit of detection.”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plainn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The third dose of BNT162b2 also increased neutralizing activity against Beta, Delta, and Wuhan pseudoviruses, with GMTs of 279, 413, and 368, respectively.”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“both being immunodominant targets of neutralizing antibodies elicited by COVID-19 vaccines or by SARS-CoV-2 infection (5, 6).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [5] L. Premkumar, B. Segovia-Chumbez, R. Jadi, D. R. Martinez, R. Raut, A. Markmann, C. Cornaby, L. Bartelt, S. Weiss, Y. Park, C. E. Edwards, E. Weimer, E. M. Scherer, N. Rouphael, S. Edupuganti, D. Weiskopf, L. V. Tse, Y. J. Hou, D. Margolis, A. Sette, M. H. Collins, J. Schmitz, R. S. Baric, A. M. de Silva, The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020). 10.1126/sciimmunol.abc8413 32527802 PMC7292505 source
- Not checked yetcites [6] W. T. Harvey, A. M. Carabelli, B. Jackson, R. K. Gupta, E. C. Thomson, E. M. Harrison, C. Ludden, R. Reeve, A. Rambaut, S. J. Peacock, D. L. Robertson; COVID-19 Genomics UK (COG-UK) Consortium, SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409– 424 (2021). 10.1038/s41579-021-00573-0 34075212 PMC8167834 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“and to elicit strong antibody responses, effectively neutralizing the parental strain as well as diverse SARS-CoV-2 VOCs (13–15).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [13] A. Muik, A.-K. Wallisch, B. Sänger, K. A. Swanson, J. Mühl, W. Chen, H. Cai, D. Maurus, R. Sarkar, Ö. Türeci, P. R. Dormitzer, U. Şahin, Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371, 1152– 1153 (2021). 10.1126/science.abg6105 33514629 PMC7971771 source
- Not checked yetcites [14] J. Liu, Y. Liu, H. Xia, J. Zou, S. C. Weaver, K. A. Swanson, H. Cai, M. Cutler, D. Cooper, A. Muik, K. U. Jansen, U. Sahin, X. Xie, P. R. Dormitzer, P.-Y. Shi, BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273– 275 (2021). 10.1038/s41586-021-03693-y 34111888 source
- Not checked yetcites [15] Y. Liu, J. Liu, H. Xia, X. Zhang, C. R. Fontes-Garfias, K. A. Swanson, H. Cai, R. Sarkar, W. Chen, M. Cutler, D. Cooper, S. C. Weaver, A. Muik, U. Sahin, K. U. Jansen, X. Xie, P. R. Dormitzer, P.-Y. Shi, Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. 384, 1466– 1468 (2021). 10.1056/NEJMc2102017 33684280 PMC7944950 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of two 30-μg doses of BNT162b2 was shown to have 95% efficacy in a phase 3 trial (12)”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [12] F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck Jr., L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, W. C. Gruber; C4591001 Clinical Trial Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603– 2615 (2020). 10.1056/NEJMoa2034577 33301246 PMC7745181 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Fifteen mutations are located in the receptor binding domain and another eight mutated sites are found in the N-terminal domain”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [4] WHO Headquarters, WHO Health Emergencies Programme, “Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States” (2021); www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Some amino acid changes [Δ69/70, T95I, G142D, Δ145, K417N, T478K, N501Y, and P681H (T, Thr; I, Ile; G, Gly; D, Asp; K, Lys; N, Asn; Y, Tyr; P, Pro; H, His)] are shared mutations also found in the Alpha, Beta (B.1.351), Gamma (P.1), or Delta VOCs and were described to lead to increased transmissibility, as well as to a typically mild partial escape from vaccine-induced humoral immunity (7–10).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [7] P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S. Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang, D. D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130– 135 (2021). 10.1038/s41586-021-03398-2 33684923 source
- Not checked yetcites [8] D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, N. Kassis-Chikhani, D. Edriss, L. Belec, A. Seve, L. Courtellemont, H. Péré, L. Hocqueloux, S. Fafi-Kremer, T. Prazuck, H. Mouquet, T. Bruel, E. Simon-Lorière, F. A. Rey, O. Schwartz, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276– 280 (2021). 10.1038/s41586-021-03777-9 34237773 source
- Not checked yetcites [9] Q. Wang, M. S. Nair, S. Anang, S. Zhang, H. Nguyen, Y. Huang, L. Liu, D. D. Ho, J. G. Sodroski, Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. iScience 24, 103393 (2021). 10.1016/j.isci.2021.103393 34746689 PMC8559451 source
- Not checked yetcites [10] A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. D. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, Z. Liu, S. P. J. Whelan, R. H. Carnahan, J. E. Crowe Jr., J. D. Bloom, Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe 29, 44– 57.e9 (2021). 10.1016/j.chom.2020.11.007 33259788 PMC7676316 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Omicron is a highly divergent variant and harbors a previously unseen number of mutations in its spike (S) glycoprotein (4).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [4] WHO Headquarters, WHO Health Emergencies Programme, “Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States” (2021); www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [7] P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S. Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang, D. D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130– 135 (2021). 10.1038/s41586-021-03398-2 33684923 source
- Not checked yetcites [19] L. J. Abu-Raddad, H. Chemaitelly, A. A. Butt; National Study Group for COVID-19 Vaccination, Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 385, 187– 189 (2021). 10.1056/NEJMc2104974 33951357 PMC8117967 source
- Not checked yetcites [20] O. Mor, N. S. Zuckerman, I. Hazan, R. Fluss, N. Ash, N. Ginish, E. Mendelson, S. Alroy-Preis, L. Freedman, A. Huppert, BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals. J. Clin. Epidemiol. 142, 38– 44 (2022). 10.1016/j.jclinepi.2021.10.011 34715314 PMC8553421 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In the analysis presented here, we have evaluated and compared serum panels from different clinical trials with a limited sample size.”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Each specimen was tested in duplicate, and geometric mean 50% pseudovirus-neutralizing titers (GMTs) were plotted.”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“but the time elapsed between the second and third doses was not consistent across participants.”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“T cell responses play a vital role as a second layer of defense, in particular in the prevention of severe COVID-19 (26).”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
What the sources say
- Not checked yetcites [26] A. Bertoletti, N. Le Bert, M. Qui, A. T. Tan, SARS-CoV-2-specific T cells in infection and vaccination. Cell. Mol. Immunol. 18, 2307– 2312 (2021). 10.1038/s41423-021-00743-3 34471260 PMC8408362 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Class I epitopes that are unchanged at the amino acid sequence level remain recognized by vaccine-elicited CD8+ T cells.
“Despite the multitude of mutations in the Omicron S protein, 85.3% (n = 208) of the described class I epitopes were not affected on the amino acid sequence level, indicating that the targets of most T cell responses elicited by BNT162b2 may still be conserved in the Omicron variant (fig. S3).”
“our analyses suggest that CD8+ T cell recognition of Omicron S glycoprotein epitopes is largely preserved.”
The paper relies on this without support.
Sera from different clinical trials are comparable for neutralizing antibody analysis.
“we have evaluated and compared serum panels from different clinical trials with a limited sample size.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neutralization titers induced after two doses of BNT162b2 were 160, 7, 24, and 73 GMTs for wild-type SARS-CoV-2, Omicron, Beta, and Delta variants, respectively”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [406]
In the citing paper
“but improved to 368, 164, 279, and 413 GMTs, after one month following a booster vaccination.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [406]
In the citing paper
“In all cases, neutralizing antibody titers after the second dose of mRNA-based vaccines were highly reduced for omicron (B.1.1.529) compared with delta (B.1.617.2) and especially compared with the wild-type variant, while the third dose significantly improved antibody neutralization titers.110,112,113”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [113]
In the citing paper
“Comparable trends were observed in live virus neutralization testing.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [406]
In the citing paper
“Thus vaccine booster with BNT162b2 may enhance neutralization of the Omicron variant.406”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [406]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“were reduced 3.4-fold compared with those against the Wuhan reference at 21 days after two doses of BNT162b2 (GMT of 106 versus 368)”
§ Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera > Abstract
Reported 3.4 · recomputed 3.471698
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationKhoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
GISAID’s Role in Pandemic Response
Khare, S., GISAID Global Data Science Initiative (GISAID), M., Gurry, C., Freitas, L. A., Schultz, M. B., Bach, G., Diallo, A. B., Akite, N., Ho, J., Lee, R. T., et al. (2021) · China CDC Weekly · doi:10.46234/ccdcw2021.255 · Cited by 1,023
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
Research works printed but not linked: 1
- https://doi.org/10.1101/2021.12.08.21267417.10.1101/2021.12.08.21267417 2021.12.08.21267417 · DOI · Paper page
Cited by
Sorted by citations
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Fan, Y., Li, X., Zhang, L., Wan, S., Zhang, L., & Zhou, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00997-x · Cited by 599
Shrestha, L. B., Foster, C. S. P., Rawlinson, W. D., Tedla, N. T., & Bull, R. A. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2381 · Cited by 483
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Tang, J., Zeng, C., Cox, T. M., Li, C., Son, Y. M., Cheon, I. S., Wu, Y., Behl, S., Taylor, J. J., Chakaraborty, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.add4853 · Cited by 364
Buchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.32760 · Cited by 356
Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., et al. (2022) · Science · doi:10.1126/science.abq1841 · Cited by 325
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy
You, Y., Tian, Y., Yang, Z., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Cao, J., Hsu, W.-H., Liu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00989-w · Cited by 258
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
Goel, R. R., Painter, M. M., Lundgreen, K. A., Apostolidis, S. A., Baxter, A. E., Giles, J. R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.009 · Cited by 207
Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 209
Quandt, J., Muik, A., Salisch, N. C., Lui, B. G., Lutz, S., Krüger, K., Wallisch, A.-K., Adams‐Quack, P., Bacher, M., Finlayson, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq2427 · Cited by 194
Self-citationThe Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 193
Self-citationSARS-CoV-2 Omicron boosting induces de novo B cell response in humans
Alsoussi, W. B., Malladi, S. K., Zhou, J. Q., Liu, Z., Ying, B., Kim, W., Schmitz, A. J., Lei, T., Horvath, S. C., Sturtz, A. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06025-4 · Cited by 174
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 168
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 149
Gilboa, M., Regev-Yochay, G., Mandelboim, M., Indenbaum, V., Asraf, K., Fluss, R., Amit, S., Mendelson, E., Doolman, R., Afek, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31778 · Cited by 128
Dhawan, M. K., Saied, A. A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., & Wilairatana, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113522 · Cited by 130
RetractedBuchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · doi:10.1101/2021.12.30.21268565 · Cited by 356
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 111
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8590 · Cited by 115
van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003991 · Cited by 104
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 120
Schubert, M., Bertoglio, F., Steinke, S., Heine, P. A., Ynga-Durand, M. A., Maaß, H., Sammartino, J. C., Cassaniti, I., Zuo, F., Du, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02312-5 · Cited by 92
Sullivan, D. J., Franchini, M., Joyner, M. J., Casadevall, A., & Focosi, D. (2022) · Nature Communications · doi:10.1038/s41467-022-33864-y · Cited by 92
Zhou, H., Møhlenberg, M., Thakor, J. C., Tuli, H. S., Wang, P., Assaraf, Y. G., Dhama, K., & Jiang, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-22 · Cited by 78
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 82
Pitts, J., Li, J., Perry, J. K., Pont, V. D., Riola, N. C., Rodriguez, L., Lu, X., Kurhade, C., Xie, X., Camus, G., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00222-22 · Cited by 72
A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant
He, C., Yang, J., Hong, W., Chen, Z., Peng, D., Hong, L., Alu, A., He, X., Bi, Z., Jiang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33209-9 · Cited by 75
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Chavda, V. P., Vuppu, S., Mishra, T., Kamaraj, S., Patel, A., Sharma, N., & Chen, Z. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00425-5 · Cited by 73
Brüssow, H. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14064 · Cited by 70
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Finlayson, A., Krüger, K., Ozhelvaci, O., Grikscheit, K., Hoehl, S., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade2283 · Cited by 71
Self-citationLee, I., Sun, C., Wu, P., Lan, Y.-H., Wang, I.-H., Liu, W., Yuan, J. P., Chang, Y.-W., Tseng, S.-C., Tsung, S.-I., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00830-1 · Cited by 66
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
Kared, H., Wolf, A., Alirezaylavasani, A., Ravussin, A., Solum, G., Tran, T. T., Lund‐Johansen, F., Vaage, J. T., Nissen‐Meyer, L. S. H., Nygaard, U. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31888-y · Cited by 65
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population
Wei, J., Stoesser, N. E., Matthews, P. C., Khera, T. K., Gethings, O., Diamond, I. D., Studley, R., Taylor, N. P., Peto, T., Walker, A. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44973-1 · Cited by 72
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review
Wu, P., Huang, I., Wang, C., Tsai, C.-C., Chung, W.-H., & Chen, C. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00721-z · Cited by 65
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Bayani, F., Hashkavaei, N. S., Arjmand, S., Rezaei, S., Uskoković, V., Alijanianzadeh, M., Uversky, V. N., Siadat, S. O. R., Mozaffari‐Jovin, S., & Sefidbakht, Y. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.02.004 · Cited by 67
Vaccination and immunotherapies in neuroimmunological diseases
Winkelmann, A., Loebermann, M., Barnett, M. H., Hartung, H., & Zettl, U. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00646-5 · Cited by 64
Tang, R., Zheng, H., Wang, B., Gou, J.-B., Guo, X., Chen, X., Chen, Y., Wu, S., Zhong, J., Pan, H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00049-8 · Cited by 63
Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W. W.-G., & Zhang, Y. (2023) · Viruses · doi:10.3390/v15081760 · Cited by 64
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
Dickey, T. H., Tang, W. K., Butler, B., Ouahes, T., Orr-Gonzalez, S., Salinas, N. D., Lambert, L., & Tolia, N. H. (2022) · Science Advances · doi:10.1126/sciadv.abq8276 · Cited by 59
Pather, S., Madhi, S. A., Cowling, B. J., Moss, P. A. H., Kamil, J. P., Ciesek, S., Muik, A., & Türeci, Ö. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130539 · Cited by 63
Self-citationRénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62
Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.069 · Cited by 56
Recent insights into SARS‐CoV‐2 omicron variant
da Silva, S. J. R., Kohl, A., Pena, L., & Pardee, K. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2373 · Cited by 56
Sentis, C., Billaud, G., Bal, A., Frobert, É., Bouscambert‐Duchamp, M., Destras, G., Josset, L., Lina, B., Morfin, F., Gaymard, A., et al. (2022) · Viruses · doi:10.3390/v14050919 · Cited by 53
Sokal, A., Broketa, M., Barba-Spaeth, G., Meola, A., Fernández, I., Fourati, S., Azzaoui, I., de La Selle, A., Vandenberghe, A., Roeser, A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.002 · Cited by 50
Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics
Kudriavtsev, A. V., Vakhrusheva, A., Novoseletsky, V. N., Bozdaganyan, M. E., Шайтан, К. В., Kirpichnikov, M. P., & Sokolova, O. S. (2022) · Viruses · doi:10.3390/v14081603 · Cited by 52
Wang, C. Y., Peng, W., Kuo, B.-S., Ho, Y.-H., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., & Hwang, K. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1010870 · Cited by 48
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 47
Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.10780 · Cited by 47
Dhawan, M. K., Rabaan, A. A., Fawarah, M. M., Almuthree, S. A., Alsubki, R. A., Alfaraj, A. H., Mashraqi, M. M., Alshamrani, S., Abduljabbar, W. A., Alwashmi, A. S. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11010101 · Cited by 45
Lapa, D., Grousova, D. M., Matusali, G., Meschi, S., Colavita, F., Bettini, A., Gramigna, G., Francalancia, M., Garbuglia, A. R., Girardi, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10050817 · Cited by 44
A comparative overview of SARS‑CoV‑2 and its variants of concern
Ahmad, A., Fawaz, M. A. M., & Aisha, A. (2022) · Infezioni in Medicina · doi:10.53854/liim-3003-2 · Cited by 50
Hawman, D. W., Meade-White, K. D., Clancy, C. S., Archer, J. F., Hinkley, T. C., Leventhal, S. S., Rao, D., Stamper, A., Lewis, M. C., Rosenke, R., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104196 · Cited by 43
Marking, U. W., Havervall, S., Greilert‐Norin, N., Bladh, O., Christ, W., Gordon, M., Ng, H., Blom, K. G., Phillipson, M., Mangsbo, S. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36984-1 · Cited by 45
Chen, Z., Zhang, Y., Wang, M., Islam, M. S., Liao, P., Hu, Y., & Chen, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73583 · Cited by 42
Inoue, T., Shinnakasu, R., Chie, K., Yamamoto, H. H., Sakakibara, S., Ono, C., Itoh, Y., Terooatea, T. W., Yamashita, K., Okamoto, T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221786 · Cited by 45
Wei, J., Matthews, P. C., Stoesser, N. E., Newton, J. N., Diamond, I. D., Studley, R., Taylor, N. P., Bell, J. I., Farrar, J., Kolenchery, J. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38275-1 · Cited by 43
COVID-19: From emerging variants to vaccination
Senevirathne, T. H., Wekking, D., Swain, J. W. R., Solinas, C., & Silva, P. D. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.005 · Cited by 45
Wang, J., Deng, C., Liu, M., Liu, Y., Li, L., Huang, Z., Shang, L., Jiang, J., Li, Y., Mo, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34633-7 · Cited by 45
SARS‐CoV‐2 Omicron and its current known unknowns: A narrative review
Le, T. T. B., Vasanthakumaran, T., Hau, N. T. H., Hung, I., Luu, M. N., Khan, Z. A., An, N. T., Tran, V. P., Lee, W. J., Aziz, J. M. A., et al. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2398 · Cited by 42
Reis, H. Ç., & Turk, V. (2022) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2022.102427 · Cited by 40
Mwimanzi, F. M., Lapointe, H. R., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac199 · Cited by 40
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 42
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
Bakasis, A., Bitzogli, K., Mouziouras, D., Pouliakis, A., Roumpoutsou, M., Goules, A. V., & Ανδρουτσάκος, Θ. (2022) · Viruses · doi:10.3390/v14020207 · Cited by 37
Muik, A., Lui, B. G., Quandt, J., Diao, H., Fu, Y., Bacher, M., Gordon, J., Toker, A., Grosser, J., Ozhelvaci, O., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112888 · Cited by 37
Self-citationMuik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Cadima-Couto, Í., Güler, A., Mampilli, V., Schmitt, G. J., Mottl, J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade9888 · Cited by 36
Self-citationGe, K., Bai, Z., Wang, J., Li, Z., Gao, F., Liu, S., Zhang, L., Gao, F., & Xie, C. (2025) · Advanced Materials · doi:10.1002/adma.202418872 · Cited by 36
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
Sadeghalvad, M., Mansourabadi, A. H., Noori, M., Nejadghaderi, S. A., Masoomikarimi, M., Alimohammadi, M., & Rezaei, N. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2359 · Cited by 35
Mair, M. J., Berger, J. M., Mitterer, M., Gansterer, M., Bathke, A. C., Trutschnig, W., Berghoff, A. S., Perkmann, T., Haslacher, H., Lamm, W. W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.019 · Cited by 34
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Takheaw, N., Liwsrisakun, C., Chaiwong, W., Laopajon, W., Pata, S., Inchai, J., Duangjit, P., Pothirat, C., Bumroongkit, C., Deesomchok, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12061315 · Cited by 34
Tauzin, A., Nicolas, A., Ding, S., Benlarbi, M., Medjahed, H., Chatterjee, D., Dionne, K., Gong, S. Y., Gendron‐Lepage, G., Bo, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.111998 · Cited by 34
Sokal, A., Spaeth, G. B., Hunault, L., Fernández, I., Broketa, M., Meola, A., Fourati, S., Azzaoui, I., Vandenberghe, A., Lagouge-Roussey, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.007 · Cited by 37
Shen, X. (2022) · Nature Medicine · doi:10.1038/s41591-022-01727-0 · Cited by 34
Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant
Lippi, G., Mattiuzzi, C., & Henry, B. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27575 · Cited by 33
Mader, A.-L., Tydykov, L., Glück, V., Bertok, M., Weidlich, T., Gottwald, C., Stefl, A., Vogel, M., Plentz, A., Köstler, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104076 · Cited by 33
Favresse, J., Gillot, C., Bayart, J., David, C., Simon, G., Wauthier, L., Closset, M., Dogné, J., & Douxfils, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28164 · Cited by 33
Mrak, D., Simader, E., Sieghart, D., Mandl, P., Radner, H., Perkmann, T., Haslacher, H., Mayer, M., Koblischke, M., Hofer, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222579 · Cited by 32
Vogel, E., Kocher, K., Priller, A., Cheng, C., Steininger, P. A., Liao, B., Körber, N., Willmann, A., Irrgang, P., Held, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104294 · Cited by 31
Azeem, M. I., Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Potdar, S. V., Manalo, R. J., Moreno, A., Switchenko, J. M., Cheedarla, S., Doxie, D. B., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0173 · Cited by 31
Pratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30
Xu, H., Li, H., You, H., Zhang, P., Li, N., Jiang, N., Cao, Y., Qin, L., Qin, G., Qu, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2149935 · Cited by 29
Poveda, C., Leão, A. C., Mancino, C., Taraballi, F., Chen, Y., Adhikari, R., Villar, M. J., Kundu, R. T., Nguyen, D. M., Versteeg, L., et al. (2023) · Current Research in Immunology · doi:10.1016/j.crimmu.2023.100066 · Cited by 29
Guirakhoo, F., Wang, S., Wang, C. Y., Kuo, H. K., Peng, W. J., Liu, H., Wang, L., Johnson, M., Hunt, A., Hu, M. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac241 · Cited by 28
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Xu, A., Hong, B., Lou, F., Wang, S., Li, W., Shafqat, A., An, X., Zhao, Y., Song, L., Tong, Y., et al. (2022) · MedComm · doi:10.1002/mco2.172 · Cited by 30
Syversen, S. W., Jyssum, I., Tveter, A. T., Sexton, J., Christensen, I. E., Tran, T. T., Bjørlykke, K. H., Mjaaland, S., Warren, D. J., Kvien, T. K., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002417 · Cited by 29
Matusali, G., Sberna, G., Meschi, S., Gramigna, G., Colavita, F., Lapa, D., Francalancia, M., Bettini, A., Capobianchi, M. R., Puro, V., et al. (2022) · Viruses · doi:10.3390/v14020312 · Cited by 27
Lü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 28
Dapporto, F., Marchi, S., Leonardi, M., Piu, P., Lovreglio, P., Decaro, N., Buonvino, N., Stufano, A., Lorusso, E., Bombardieri, E., et al. (2022) · Journal of Immunology Research · doi:10.1155/2022/4813199 · Cited by 27
Rajpal, V. R., Sharma, S., Kumar, A., Chand, S., Joshi, L., Chandra, A., Babbar, S., Goel, S., Raina, S. N., & Shiran, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27749 · Cited by 26
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review
Du, Y., Chen, L., & Shi, Y. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2062983 · Cited by 26
Metadata
- Authors
- Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., Shpyro, S., Finlayson, A., Cai, H., Yang, Q., Swanson, K. A., Türeci, Ö., & Şahin, U.
- Affiliations
- BioNTech (Germany) (DE)
- BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
- BioNTech (United States) (US)
- Pfizer (United States) (US)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Şahin, Uğur
- ORCID
- Venue
- Science
- Published
- 2022-02-11
- Volume
- 375
- Issue
- 6581
- Pages
- 678-680
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9836206
- OpenAlex
- W4205283268
- Semantic Scholar
- 31ac060c1da1a7151d25d210ffb13c5366317bbf
- Cited by
- 367
- References
- 29
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 40 · 2023: 103 · 2022: 190
- FWCI
- 43.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- Omicron variant, BNT162b2 mRNA vaccine, neutralizing antibodies, third vaccine dose, spike protein mutations, COVID-19 protection, pseudovirus neutralization
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Humans, Immunization Schedule, Immunization, Secondary, Middle Aged, Mutation, Neutralization Tests, T-Lymphocytes, Vaccination, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
